FA
Forefront Analytics’s CytomX Therapeutics CTMX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $62.9K | Sell |
27,698
-72,372
| -72% | -$164K | 0.07% | 40 |
|
|
2025
Q1 | $63.1K | Buy |
100,070
+35,811
| +56% | +$22.6K | 0.07% | 43 |
|
|
2024
Q4 | $66.2K | Buy |
64,259
+4,499
| +8% | +$4.63K | 0.03% | 64 |
|
|
2024
Q3 | $70.5K | Sell |
59,760
-4,305
| -7% | -$5.08K | 0.03% | 66 |
|
|
2024
Q2 | $78.2K | Buy |
64,065
+43,176
| +207% | +$52.7K | 0.04% | 67 |
|
|
2024
Q1 | $45.5K | Sell |
20,889
-9,957
| -32% | -$21.7K | 0.02% | 67 |
|
|
2023
Q4 | $47.8K | Sell |
30,846
-18,575
| -38% | -$28.8K | 0.02% | 67 |
|
|
2023
Q3 | $63.8K | Sell |
49,421
-175
| -0.4% | -$226 | 0.04% | 61 |
|
|
2023
Q2 | $85.3K | Buy |
49,596
+23,184
| +88% | +$39.9K | 0.05% | 59 |
|
|
2023
Q1 | $39.9K | Buy |
26,412
+1,625
| +7% | +$2.45K | 0.02% | 77 |
|
|
2022
Q4 | $39.7K | Sell |
24,787
-23,082
| -48% | -$36.9K | 0.02% | 71 |
|
|
2022
Q3 | $71K | Buy |
47,869
+11,950
| +33% | +$17.7K | 0.04% | 57 |
|
|
2022
Q2 | $67K | Buy |
35,919
+21,275
| +145% | +$39.7K | 0.03% | 58 |
|
|
2022
Q1 | $40K | Buy |
14,644
+900
| +7% | +$2.46K | 0.01% | 68 |
|
|
2021
Q4 | $62K | Buy |
13,744
+350
| +3% | +$1.58K | 0.02% | 61 |
|
|
2021
Q3 | $68K | Buy |
+13,394
| New | +$68K | 0.02% | 63 |
|